Title
Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study
Date Issued
01 February 2021
Access level
open access
Resource Type
journal article
Author(s)
Rouzé A.
Martin-Loeches I.
Povoa P.
Makris D.
Artigas A.
Bouchereau M.
Lambiotte F.
Metzelard M.
Cuchet P.
Boulle Geronimi C.
Labruyere M.
Tamion F.
Nyunga M.
Luyt C.E.
Labreuche J.
Pouly O.
Bardin J.
Saade A.
Asfar P.
Baudel J.L.
Beurton A.
Garot D.
Ioannidou I.
Kreitmann L.
Llitjos J.F.
Magira E.
Mégarbane B.
Meguerditchian D.
Moglia E.
Mekontso-Dessap A.
Reignier J.
Turpin M.
Pierre A.
Plantefeve G.
Vinsonneau C.
Floch P.E.
Weiss N.
Ceccato A.
Torres A.
Duhamel A.
Nseir S.
Favory R.
Preau S.
Jourdain M.
Poissy J.
Bouras C.
Saint Leger P.
Fodil H.
Aptel F.
Van Der Linden T.
Thille A.W.
Azoulay E.
Pène F.
Razazi K.
Bagate F.
Contou D.
Voiriot G.
Thevenin D.
Guidet B.
Le Guennec L.
Kouatchet A.
Ehrmann S.
Brunin G.
Morawiec E.
Boyer A.
Argaud L.
Voicu S.
Nieszkowska A.
Kowalski B.
Goma G.
Diaz E.
Morales L.
Tsolaki V.
Gtavriilidis G.
Mentzelopoulos S.D.
Nora D.
Boyd S.
Coelho L.
Maizel J.
Du Cheyron D.
Imouloudene M.
Quenot J.P.
Guilbert A.
Publisher(s)
Springer Science and Business Media Deutschland GmbH
Abstract
Purpose: Although patients with SARS-CoV-2 infection have several risk factors for ventilator-associated lower respiratory tract infections (VA-LRTI), the reported incidence of hospital-acquired infections is low. We aimed to determine the relationship between SARS-CoV-2 pneumonia, as compared to influenza pneumonia or no viral infection, and the incidence of VA-LRTI. Methods: Multicenter retrospective European cohort performed in 36 ICUs. All adult patients receiving invasive mechanical ventilation > 48 h were eligible if they had: SARS-CoV-2 pneumonia, influenza pneumonia, or no viral infection at ICU admission. VA-LRTI, including ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP), were diagnosed using clinical, radiological and quantitative microbiological criteria. All VA-LRTI were prospectively identified, and chest-X rays were analyzed by at least two physicians. Cumulative incidence of first episodes of VA-LRTI was estimated using the Kalbfleisch and Prentice method, and compared using Fine-and Gray models. Results: 1576 patients were included (568 in SARS-CoV-2, 482 in influenza, and 526 in no viral infection groups). VA-LRTI incidence was significantly higher in SARS-CoV-2 patients (287, 50.5%), as compared to influenza patients (146, 30.3%, adjusted sub hazard ratio (sHR) 1.60 (95% confidence interval (CI) 1.26 to 2.04)) or patients with no viral infection (133, 25.3%, adjusted sHR 1.7 (95% CI 1.2 to 2.39)). Gram-negative bacilli were responsible for a large proportion (82% to 89.7%) of VA-LRTI, mainly Pseudomonas aeruginosa, Enterobacter spp., and Klebsiella spp. Conclusions: The incidence of VA-LRTI is significantly higher in patients with SARS-CoV-2 infection, as compared to patients with influenza pneumonia, or no viral infection after statistical adjustment, but residual confounding may still play a role in the effect estimates.
Start page
188
End page
198
Volume
47
Issue
2
Language
English
OCDE Knowledge area
Enfermedades infecciosas Medicina clínica
Scopus EID
2-s2.0-85098496448
PubMed ID
Source
Intensive Care Medicine
ISSN of the container
03424642
Sponsor(s)
Raphaël Favory: CHU de Lille, Centre de Réanimation, F-59000 Lille, France, Sébastien Preau: CHU de Lille, Centre de Réanimation, F-59000 Lille, France, Mercé Jourdain: CHU de Lille, Centre de Réanimation, F-59000 Lille, France, Julien Poissy: CHU de Lille, Centre de Réanimation, F-59000 Lille, France, Chaouki Bouras: Service de Réanimation polyvalente, Centre Hospitalier de Valenciennes, Valenciennes, France, Piehr Saint Leger: Service de Réanimation polyvalente, Centre Hospitalier de Valenciennes, Valenciennes, France, Hanane Fodil: Service de Réanimation polyvalente, Centre Hospitalier de Valenciennes, Valenciennes, France, François Aptel: Department of Intensive Care, François Mitterrand University Hospital, Dijon, France, Thierry Van Der Linden: Médecine intensive réanimation, Hôpital Saint Philibert GHICL, Université catholique, Lille, France, Arnaud W. Thille: CHU de Poitiers, Médecine Intensive Réanimation, CIC 1402 ALIVE, Université de Poitiers, Poitiers, France, Elie Azoulay: Service de médecine intensive et réanimation, hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75010, Paris, France, Frédéric Pene: Medical Intensive Care Unit, Cochin Hospital, AP-HP. Centre, & Université de Paris, Paris, France. This study was supported in part by a grant from the French government through the « Programme Investissement d’Avenir» (I-SITE ULNE) managed by the Agence Nationale de la Recherche (coVAPid project). The funders of the study had no role in the study design, data collection, analysis, or interpretation, writing of the report, or decision to submit for publication. AR received personal fees from MaatPharma, IML received personal fees from MSD, and Gilead. AA received personal fees from Lilly Foundation, and grants from Grifols and Fischer & Paykel. CEL received personal fees from Bayer, Merck, Aerogen, Biomérieux, ThermoFischer Brahms, and Carmat. NW received personal fees from MedDay pharmaceuticals. SN received personal fees from MSD, Bio Rad, BioMérieux, Gilead, and Pfizer. All other authors declare no competing interests.
Sources of information: Directorio de Producción Científica Scopus